ArticleImmunology2002
Type I interferon gene therapy protects against cytomegalovirus-induced myocarditis.
Article in Immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Parkinson's disease, herpes simplex virus type 1, and nanopore sequencing: A case analysis.Biochemistry and biophysics reports · 2025Article
- IFNα Subtypes in HIV Infection and Immunity.Viruses · 2024Review
- IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies.Frontiers in immunology · 2021Article
- Diverse Anti-Tumor Immune Potential Driven by Individual IFNα Subtypes.Frontiers in immunology · 2020Article
- Article
- SOCS and Herpesviruses, With Emphasis on Cytomegalovirus Retinitis.Frontiers in immunology · 2019Review
- Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.Frontiers in immunology · 2018Review
- CD8Frontiers in immunology · 2018Article
- Different antiviral effects of IFNα subtypes in a mouse model of HBV infection.Scientific reports · 2017Article
- Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis.PloS one · 2014Article
- Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection.PloS one · 2014Article
- Persistent and compartmentalised disruption of dendritic cell subpopulations in the lung following influenza A virus infection.PloS one · 2014Article
- Viral myocarditis: from experimental models to molecular diagnosis in patients.Heart failure reviews · 2013Review
- IFN-α subtypes: distinct biological activities in anti-viral therapy.British journal of pharmacology · 2013Review
- Improved vaccine protection against retrovirus infection after co-administration of adenoviral vectors encoding viral antigens and type I interferon subtypes.Retrovirology · 2011Article
- The early interferon alpha subtype response in infant macaques infected orally with SIV.Journal of acquired immune deficiency syndromes (1999) · 2010Article
- IFN-alpha expression and antiviral effects are subtype and cell type specific in the cardiac response to viral infection.Virology · 2010Article
- Interferon-beta suppresses herpes simplex virus type 1 replication in trigeminal ganglion cells through an RNase L-dependent pathway.Journal of neuroimmunology · 2003Article
- Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice.Gene therapy · 2002Article
- Differential effect of murine alpha/beta interferon transgenes on antagonization of herpes simplex virus type 1 replication.Journal of virology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type I interferons (IFNs) are produced early in response to viral infection and modulate adaptive immunity. Previously we demonstrated localized protection against murine cytomegalovirus (MCMV) infection in IFN DNA-inoculated mice. Here we examine the effect of seven IFN subtypes (IFNA1, A2, A4, A5, A6, A9 and B), administered by DNA inoculation, on systemic MCMV infection and myocarditis. IFN transgene expression altered the pathogenesis of MCMV infection with regard to virus titre and myocarditis. IFNA6 treatment reduced MCMV replication whilst IFNA5 and A2 enhanced virus replication. IFNA6, A9, and B treatment inhibited acute myocarditis. A T helper type 1-like, antibody and cytokine, response correlated with decreased virus titre and myocarditis. In addition, IFNA6 was able to reduce chronic cardiac inflammation. This research into the effectiveness of seven type I IFNs, using DNA gene therapy, highlights the need for correct subtype usage in the treatment of disease. We demonstrate effective subtypes for treatment in both the acute and chronic phases of MCMV infection and the resultant development of myocarditis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.